AEON Biopharma Doses First Patient in Phase 2 Trial of ABP-450 for the Treatment of Cervical Dystonia
-Topline data expected in early-2022-NEWPORT BEACH, Calif., April 05, 2021 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc., a private clinical-stage biopharmaceutical...